29 January 2026
29 January 2026
Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.
The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011.
Sanofi’s participation will support the progression of Sensorion’s genetic medicine pipeline.
The Phase III AMETHYST study is currently assessing litifilimab’s safety and efficacy, with results anticipated in 2027.
The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
